Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status

Triple negative breast cancer (TNBC) is a deadly disease with limited treatment options. Selinexor is a selective inhibitor of nuclear export that binds covalently to exportin 1 thereby reactivating tumor suppressor proteins and downregulating expression of oncogenes and DNA damage repair (DDR) prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Marijon, Hélène, Gery, Sigal, Chang, Hua, Landesman, Yosef, Shacham, Sharon, Lee, Dhong Hyun, de Gramont, Aimery, Koeffler, Harold Phillip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416554/
https://www.ncbi.nlm.nih.gov/pubmed/34504648
http://dx.doi.org/10.18632/oncotarget.28047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416554/
https://www.ncbi.nlm.nih.gov/pubmed/34504648
http://dx.doi.org/10.18632/oncotarget.28047

Ejemplares similares